Short Review

The safety, immunological benefits, and efficacy of ginseng in organ transplantation

Sun Woo Lim 1,2, Kang Luo 1,2, Yi Quan 1,2, Sheng Cui 1,2, Yoo Jin Shin 1,2, Eun Jeong Ko 1,2,3, Byung Ha Chung 1,2,3, Chul Woo Yang 1,2,3,*

1 Convergent Research Consortium for Immunologic Disease, Seoul St. Mary’s Hospital, The College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2 Transplant Research Center, The College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3 Division of Nephrology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

A R T I C L E   I N F O

Article history:
Received 19 August 2019
Received in Revised form
17 January 2020
Accepted 3 February 2020
Available online 7 February 2020

Keywords:
cyclosporine A
calcineurin inhibitor
ginseng
transplantation
tacrolimus

A B S T R A C T

Korean ginseng (Panax ginseng) is associated with a variety of therapeutic effects, including antioxidative, anti-inflammatory, vasorelaxative, antiallergic, antidiabetic, and anticancer effects. Accordingly, the use of ginseng has reached an all-time high among members of the general public. However, the safety and efficacy of ginseng in transplant recipients receiving immunosuppressant drugs have still not been elucidated. Transplantation is the most challenging and complex of surgical procedures and may require causation for the use of ginseng. In this regard, we have previously examined the safety, immunological benefits, and protective mechanisms of ginseng with respect to calcineurin inhibitor-based immunosuppression, which is the most widely used regimen in organ transplantation. Using an experimental model of calcineurin inhibitor-induced organ injury, we found that ginseng does not affect drug levels in the peripheral blood and tissue, favorably regulates immune response, and protects against calcineurin inhibitor-induced nephrotoxicity and pancreatic islet injury. On the basis of our experimental studies and a review of the related literature, we propose that ginseng may provide benefits in organ transplant recipients administered calcineurin inhibitors. Through the present review, we aimed to briefly discuss our current understanding of the therapeutic benefits of ginseng related to transplant patient survival.

© 2020 The Korean Society of Ginseng. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Korean ginseng (Panax ginseng Meyer) has been spent widely as a medicinal and general health supplement for a diversity of diseases worldwide [1,2]. It is one of the most highly regarded herbs in the Orient, where it is used to promote health and general body vigor and prolong life span. The generic name “Panax” originates from the Greek word “panacea,” which denotes “cure all diseases,” and true to its name, ginseng has been certified to have wide medicinal uses, including beneficial effects in diabetes, hypertension, inflammatory diseases, and cancer [3–5], and as an immune modulator [6–9]. Nevertheless, although the therapeutic potential of ginseng has been studied extensively, its effects in transplant recipients taking immunosuppressant drugs remain undetermined.

With respect to transplantation, a calcineurin inhibitor (CNI)-based immunosuppression with cyclosporin A (CsA) and tacrolimus (Tac) is the most widely used regimen in current clinical practice, because this regimen can markedly decrease acute rejection rates and provides excellent early outcomes. However, calcineurin [10–12] lacks T cell specificity, and in addition to its immunosuppressive effects, inhibition by CNIs can induce toxicity [13]. Indeed, the notable side effects associated with the administration of CNIs can hinder the survival of long-term kidney graft and patient, and cause major additional morbidity [14]. This is the case not only in kidney transplantation but also with respect to the transplantation of nonrenal solid organs and in many other diseases requiring therapy with these drugs [15]. Thus, both the nephrotoxic and...
2. Safety aspects

Transplant patients are generally placed on a regimen of two to three immunosuppressive drugs to prevent graft rejection, along with a wide range of additional drugs for the treatment of other underlying diseases, and to counteract the side effects of CNI treatment. However, as the number of medications patients consume increases, there is a concomitant increase in the likelihood of potentially detrimental drug interactions, and indeed, such interactions have been reported in the literature since the beginning of CNIs. To date, however, the question of whether there is a established interaction between ginseng and CNIs, but there is no evidence indicating that ginseng elicits similar effects on CNIs remains unanswered.

Ginsenosides, which are the active components of ginseng, are widely agreed to be responsible for both the pharmacological activity and drug interaction potential of ginseng. Although preclinical papers have evaluated the influence of various ginsenosides on CYP, glucuronidation, and drug transport activity, the results obtained in these investigations have been mostly inconclusive, due to differences in the ginseng products used and the adopted methodologies. Moreover, the findings of drug interaction studies in humans have tended to be inconsistent and have largely yielded results that are either negative or suggestive of only weak interactions [25].

We have previously reported on the beneficial effect of red ginseng in chronic CsA-induced renal injury in mice [19]. In humans, 50 – 100 mg/kg of ginseng is the manufacturer’s recommended dose, but this dose may differ from that needed for protective action in an experimental mouse model of CsA nephropathy. Therefore, as a preliminary study, we determined the optimal dose of red ginseng in our mouse model. We subsequently examined the effects of three different doses of red ginseng (200, 400, and 800 mg/kg), and 200 and 400 mg/kg of ginseng showed beneficial effects without changing the CsA level, while the highest dose (800 mg/kg) was found to increase the CsA level in the blood and kidney tissues compared with treatment with CsA only. Furthermore, the highest dose of ginseng enhanced the expression of markers for oxidative stress and the level of fibrosis compared with the CsA only and CsA plus 200 or 400 mg/kg red ginseng-treated groups. From this study, we found the protective dose of ginseng in an experimental mouse model of CsA nephropathy. In regards to safety, importantly, we can conclude that the use of large doses of ginseng with CsA increases the side effects of CsA by increasing the CsA levels in the blood and kidneys.

Because little research has been done on drug interactions between CNIs and ginseng, we predicted the drug interactions by searching the literature for known substrates and inhibitors of metabolic enzymes. Other studies using human liver microsomes have shown that Rd is generally able to interact with drugs that are metabolized by CYP2C9 and CYP3A4, whereas CYP2C9 and CYP3A4 are suppressed by Rb1, Rb2, Rc, and Rd [26]. In contrast, clinical studies involving healthy volunteers (who received 25 mg/kg/day of ginseng) found that ginseng does not affect a number of CYP isoforms, including CYP3A4, CYP1A2, CYP2E1, and CYP2D6, although a slight inhibition of CYP2D6 has been demonstrated in elderly individuals [27,28]. There has been no established interaction between ginseng and CNIs, but there is sufficient possibility based on the literature. In spite of the generally favorable findings for ginseng, the possibility that the combination of ginseng and CNIs may cause adverse effects in tissues cannot be ruled out. Therefore, the evidence indicates that ginseng can be considered for use in renal transplant recipients taking CNIs.

**Is it OK to take Ginseng in Organ Transplant Recipients?**

1. **Safety**
   - Combination with usual dose of ginseng may not affect CNIs level

2. **Immunologic benefit**
   - Ginseng suppresses pro-inflammatory T cells, Th17 cells
   - Ginseng regulates immune tolerance by induction of Treg cells

3. **Efficacy**
   - Ginseng protects cells by reducing oxidative stress, autophagy cell death, and apoptosis during CNI-induced toxicity

Fig. 1. Conceptual summary of experimental studies using ginseng and calcineurin inhibitors. CNIs, calcineurin inhibitor; Th17, T helper 17 cell; Treg, regulatory T cells.
but patients should be carefully monitored for possible adverse reactions [19].

3. Immunological benefits

Subsequent to kidney transplantation, the alloimmune responses induced by the activation of CD4+ T cells mediate most of the allograft rejections [29]. Therefore, most immunosuppressants have been originated to suppress the activation and differentiation of effector CD4+ T cells to prevent the induction of the alloimmune responses [30,31]. In current clinical practice, the first choice immunosuppressants are CNIs (particularly Tac), and 99.1% of immunosuppressant protocols are CNI-based [32]. This is because CNIs have been shown to be more effective in inhibiting the induction of acute rejection episodes and improving 1-year allograft survival than the azathioprine and steroids [33,34].

In contrast, however, the use of CNIs has not significantly improved long-term allograft survival when compared with that achieved in the azathioprine era [14,35]. Chung et al [32] reported that Tac suppresses T helper type (Th) 1, Th2, and regulatory T (Treg) cells in a Tac level-dependent manner, although it does not inhibit Th17 cells, even at high concentrations. Accordingly, current Tac-based immunosuppression is inadequate for the suppression of Th17 cells in kidney transplant patients, and thus, dysregulation of Th17 and Tregs may be related to the development of chronic allograft dysfunction.

Ginseng is well known as an immune modulator [6–9], and the roots (primarily), stems, and leaves of ginseng, along with their various extracts, have been used for keeping immune homeostasis and promoting resistance to illness or microbial infection via immune system effects. Ginseng has recently received attention as a potential therapy for the prevention of autoimmune immune dysfunction. Ginseng has immunological benefits via the reciprocal regulation of chronic allograft dysfunction.

The same authors also examined the reciprocal regulation of Th17 cells and Tregs, whereby the relative activation of STAT3 and STAT5 directly dictates the outcome of IL-17 production in CD4+ T cells [41] during treatment with CsA and red ginseng. Interestingly, they found that the population of Th17 cell and STAT3, which is its transcription factor, were dramatically decreased by red ginseng and that the CsA-induced inhibition of Treg differentiation was significantly recovered by red ginseng.

These results thus provide evidence that supplementation with ginseng can confer a degree of immunological safety in CNI-based immunosuppression, and that ginseng plays as an immune regulator via the reciprocal regulation of Th17 and Treg cells (Fig. 2). These findings accordingly suggest a rationale for the treatment of ginseng in transplant and immune disorder patients taking CNIs.

4. The protective mechanism of ginseng

Chronic allograft injury, the main cause of kidney transplant failure, is a frequent occurrence and often results in the need for dialysis. Renal allograft failure is the most common reason for end-stage kidney disease and is a factor associated with 25% to 30% of patients waiting for kidney transplants [42]. CNI nephrotoxicity is a major contributor to chronic allograft injury, and almost all renal transplant recipients exhibit chronic CsA-induced nephropathy.

The Treg/Th17 Cell Balance: A New Paradigm for Immune Regulation

![Fig. 2. Schematic diagram summarizing the predicted mechanisms whereby ginseng influences immune regulation. Ginseng has immunological benefits via the reciprocal regulation of Th17 and Treg cells during cyclosporin A-induced immunosuppression. Th17, T helper 17 cell; Treg, regulatory T cell.](image-url)
within 10 years of the commencement of CNI treatment [43]. The use of CNIs in kidney transplant recipients is also associated with higher incidences of hypertension and dyslipidemia and an increased risk of cardiovascular events [16,44]. Overall, CNI-related complications can lead to poor long-term outcomes in kidney transplant recipients.

Oxidative stress is a common pathway underlying chronic CNI-induced nephropathy [45–47]. High levels of oxidative stress induced by chronic CsA administration have been demonstrated to cause structural and functional kidney impairment via the induction of free radical species in the kidney, which, in turn, may promote apoptotic and autophagic cell death [48–50]. Given that oxidative stress can be an important contributor to the pathogenesis of chronic diseases, the ability of ginseng and its constituent ginsenosides to improve disease symptoms via antioxidant mechanisms is of particular interest. However, the influence of ginseng on chronic CNI-induced oxidative renal injury has yet to be studied in depth. In this review, we describe the few studies that have investigated the effects of ginseng on chronic CNI-induced renal injury in general.

In a study using an experimental mouse model and a cell culture system, Doh et al [19] investigated the effect of red ginseng on chronic CsA-induced nephropathy. This study demonstrated the protective effect of red ginseng against CsA-induced renal injury in mice and treatment was associated with decreased blood urea nitrogen, interstitial inflammation, fibrosis, and apoptosis. Moreover, in vitro and in vivo results revealed that the antioxidant effect of ginseng is associated with a hold in the progression of chronic CsA-induced nephropathy. These findings provided the first evidence of a protective effect of ginseng against CsA-induced renal injury.

Lim et al, performed further experiments to elucidate the mechanism of protection of ginseng for damage caused by CNI treatment. It is known that prolonged oxidative stress caused by CNI treatment causes excessive autophagosome formation, as an adaptation to stress, as well as lysosomal dysfunction [49,51] (Fig. 3). The excessive autophagosomes resulting from CNI treatment are not effectively degraded due to the impaired lysosomal function (autophagosome fusion with lysosomes and lysosomal degradation). The resulting accumulated autophagosomes in cells lead to autophagic cell death [52]. Under these circumstances, in vitro and in vivo studies showed that ginseng treatment attenuated excess CsA-induced autophagosome formation as measured by autophagosome markers (a phospholipid-conjugated form of microtubule-associated protein light chain 3 and beclin-1) and protected lysosome function [51]. These results showed that the antioxidative effect of ginseng might contribute to reducing CNI-induced autophagic cell death (Fig. 3).

Abundant evidence indicates that oxidative stress also plays a central role in the process of biological aging [53]. In this regard, Klotho has recently been identified as an antiaging gene that is expressed primarily in the kidneys [54,55]. A reduction in the expression of this gene induces an accelerated aging-like syndrome in mice, whereas overexpression extends the life span of these animals [55–57]. To determine whether Klotho is implicated in the mechanism underlying the antiaging effect of ginseng, Lim et al [58] investigated whether ginseng upregulates Klotho and its antiaging signaling in response to Tac-induced oxidative stress. Ginseng was indeed found to reverse the Tac-induced reduction in Klotho levels in the mouse serum and kidney tissues. Tac-induced oxidative stress in an experimental mouse was thus reduced by ginseng treatment, with concomitant functional and histological improvements. In addition, in vivo and in vitro studies revealed that the Tac-induced reduction in Klotho levels promoted the PI3K/AKT-mediated phosphorylation of forkhead box O3a (FoxO3a), which appeared to be present in an inactive form in the cytoplasm. However, restoration of Klotho levels by ginseng induced the nuclear translocation of FoxO3a via the suppression of PI3K/AKT activity and an increase in manganese-dependent superoxide dismutase levels in HK-2 cells. Based on the proposed mechanism, ginseng maintained Klotho expression, thereby protecting against the oxidative damage and apoptotic cell death associated with Tac-induced toxicity. These results, therefore, provided evidence of the protective mechanism of ginseng via the antiaging gene Klotho in response to oxidative stress injury (Fig. 4).

![Fig. 3. Schematic diagram summarizing the predicted mechanism whereby ginseng influences autophagic clearance function.](image)

Prolonged oxidative stress induced by tacrolimus augments autophagosome formation as an adaptation to stress and lysosomal dysfunction. However, the autophagosomes are not effectively degraded due to impaired autophagic clearance (lysosomal degradation and autophagosome fusion with lysosomes). The resulting excess production of autophagosomes leads to autophagic cell death. Under these circumstances, ginseng treatment improves the autophagic clearance function by enhancing lysosomal function and autophagosome fusion with lysosomes. CNI, calcineurin inhibitor.
As mentioned above, although CNIs are widely used as maintenance immunosuppressants in renal transplant recipients, they can be the cause of notable metabolic abnormalities. In particular, new-onset diabetes after transplantation occurs in $10\% - 25\%$ of the patients taking Tac [59,60], thereby reducing graft survival and increasing the risk of infectious and cardiovascular diseases [61]. Although the pathogenesis of Tac-induced diabetes mellitus is currently unclear, our group and others have demonstrated that the direct toxic effects of Tac on pancreatic beta cells, together with oxidative stress, play key roles in the development of this disease [52,62–64]. Lim et al [20,51] showed that ginseng can alleviate islet dysfunction and decrease oxidative stress and autophagic vacuoles in both CsA- and Tac-induced pancreatic beta-cell injury models. Co-treatment with ginseng decreased autophagosome formation and attenuated lysosomal degradation, accompanied by improved beta-cell viability and insulin secretion in an experimental mouse model and INS-1 cells. Using INS-1 cells, Tac treatment was found to cause mitochondria dysfunction mitochondria (impaired mitochondrial oxygen consumption and ATP production, and increased reactive oxygen species production), whereas ginseng treatment was observed to improve these parameters. These findings thus indicate that ginseng has a favorable modulatory effect on autophagy by reducing the pancreatic beta-cell injury promoted by Tac-induced oxidative stress and that this effect is closely related to the amelioration of mitochondrial function. Accordingly, these results provide evidence for the beneficial effects of ginseng against CNI-induced diabetes mellitus in solid organ transplant recipients.

5. Conclusion

Although the ginseng market is currently undergoing a phase of rapid expansion, the medicinal effects of this plant are still essentially being revealed based on experience. Transplantation is the most challenging and complex of surgical procedures and may require causation for the use of ginseng. Our motivation for reviewing the current literature on the transplantation-related utility of ginseng was to provide practical guidelines for the use of ginseng in transplant patients taking immunosuppressants (Fig. 1). In this regard, using an experimental model of CNI-induced organ injury, we had previously demonstrated that ginseng does not affect drug levels in the peripheral blood and tissue, favorably regulates immune response, and protects against CNI-induced nephrotoxicity and pancreatic islet injury. Similarly, most of the studies discussed in the present review have been based on experimental animal models and/or cell lines. In contrast, few comparable studies have been undertaken using human subjects, despite the fact that ginseng products are widely believed and agreed to contain therapeutic effectiveness when used alone or in a mix with CNIs in the control of graft rejection. Nevertheless, the animal-based experimental studies do provide convincing evidence that ginseng has significant potential for use in patients with immunosuppressant-associated nephropathy and diabetes.

Conflicts of interest

All authors have no conflicts of interest to declare.

Acknowledgments

This work was supported by a 2017 grant from the Korean Society of Ginseng funded by the Korea Ginseng Corporation, the Korean Health Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (HI14C3417), and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2018R1D1A1A02043014).

References

[1] Colzani M, Altonare A, Caliendo M, Aldini G, Righetti PG, Fasoli E. The secrets of Oriental panacea: panax ginseng. J Proteomics 2016;130:150–9.
[2] Rastogi V, Santiago-Moreno J, Dore S. Ginseng: a promising neuroprotective strategy in stroke. Front Cell Neurosci 2014;8:457.
Karmazyn M, Moey M, Gan XT. Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs 2011;71:1989–2008.

Su Q, Guo M, Fei Y, Zheng H, Lei P, Ma X, Han X, Guan H, Dui D. Effect of ginseng polysaccharides on NK cell cytotoxicity in immunosuppressed mice. Exp Ther Med 2016;12:3773–7.

Kim YR, Yang CS. Protective roles of ginseng against bacterial infection. Microb Pathog 2005;39:15–9.

Jie YH, Cammisuli S, Baggiolini M. Immunomodulatory effects of Panax ginseng. Acta Pharmacol Sin 2008;29:17–26.

Kitts D, Hu C. Efficacy and safety of ginseng. Public Health Nutr 2000;3:473–85.

Su Q, Weber L, Le Hir M, Zenke G, Ryffel B. Nephrotoxicity of cyclosporin A and cyclosporine-treated patients. Am J Med 1986;81:419–24.

Wang J, Li A, Duan H, Meng Z, Tan J, Yan H, Yu Z. Human P-glycoprotein involvement in cyclosporine nephrotoxicity: association with mutual regulation of RelA (p65)/NF-kappaB and phospho-IkappaB in the CNS. Biochem Biophys Res Commun 2011;414:464–70.

Oh CH, Soo EK. Efficacy of Korean red ginseng in the treatment of alopecia areata. J Ginseng Res 2012;36:391–5.

Zhu D, Liu M, Yang Y, Ma L, Jiang Y, Zhou L, Huang Q, Pi R, Chen X. Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 2013;556:76–79.

Juhn J, Lee J, Byun JK, Kim EW, Lee JH, Kwok SK, Ju JH, Park KS, Kim HY, et al. Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17/Treg balance, and osteoclastogenesis in mice and human. Mediators Inflamm 2014;2014:31586.

Yang XP, Goreschi K, Steward-Tharp SM, Rodriguez-Canales JZ, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAG5. Nat Immunol 2011;12:247–54.

Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126–47.

Nankivel BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:349–56.

Kim YR, Yang CS. Protective roles of ginseng against bacterial infection. Microb Pathog 2005;39:15–9.

Shea JJ. T cell-directed therapies: lessons learned and future prospects. Clin Immunol 2004;108:1–12.

Wang J, Li A, Duan H, Meng Z, Tan J, Yan H, Yu Z. Human P-glycoprotein involvement in cyclosporine nephrotoxicity: association with mutual regulation of RelA (p65)/NF-kappaB and phospho-IkappaB in the CNS. Biochem Biophys Res Commun 2011;414:464–70.

Oh CH, Soo EK. Efficacy of Korean red ginseng in the treatment of alopecia areata. J Ginseng Res 2012;36:391–5.

Zhu D, Liu M, Yang Y, Ma L, Jiang Y, Zhou L, Huang Q, Pi R, Chen X. Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 2013;556:76–79.

Juhn J, Lee J, Byun JK, Kim EW, Lee JH, Kwok SK, Ju JH, Park KS, Kim HY, et al. Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17/Treg balance, and osteoclastogenesis in mice and human. Mediators Inflamm 2014;2014:31586.

Yang XP, Goreschi K, Steward-Tharp SM, Rodriguez-Canales JZ, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAG5. Nat Immunol 2011;12:247–54.

Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126–47.

Nankivel BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:349–56.

Kim YR, Yang CS. Protective roles of ginseng against bacterial infection. Microb Pathog 2005;39:15–9.

Shea JJ. T cell-directed therapies: lessons learned and future prospects. Clin Immunol 2004;108:1–12.

Wang J, Li A, Duan H, Meng Z, Tan J, Yan H, Yu Z. Human P-glycoprotein involvement in cyclosporine nephrotoxicity: association with mutual regulation of RelA (p65)/NF-kappaB and phospho-IkappaB in the CNS. Biochem Biophys Res Commun 2011;414:464–70.

Oh CH, Soo EK. Efficacy of Korean red ginseng in the treatment of alopecia areata. J Ginseng Res 2012;36:391–5.

Zhu D, Liu M, Yang Y, Ma L, Jiang Y, Zhou L, Huang Q, Pi R, Chen X. Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 2013;556:76–79.

Juhn J, Lee J, Byun JK, Kim EW, Lee JH, Kwok SK, Ju JH, Park KS, Kim HY, et al. Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17/Treg balance, and osteoclastogenesis in mice and human. Mediators Inflamm 2014;2014:31586.

Yang XP, Goreschi K, Steward-Tharp SM, Rodriguez-Canales JZ, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAG5. Nat Immunol 2011;12:247–54.

Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126–47.

Nankivel BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:349–56.

Kim YR, Yang CS. Protective roles of ginseng against bacterial infection. Microb Pathog 2005;39:15–9.

Shea JJ. T cell-directed therapies: lessons learned and future prospects. Clin Immunol 2004;108:1–12.

Wang J, Li A, Duan H, Meng Z, Tan J, Yan H, Yu Z. Human P-glycoprotein involvement in cyclosporine nephrotoxicity: association with mutual regulation of RelA (p65)/NF-kappaB and phospho-IkappaB in the CNS. Biochem Biophys Res Commun 2011;414:464–70.

Oh CH, Soo EK. Efficacy of Korean red ginseng in the treatment of alopecia areata. J Ginseng Res 2012;36:391–5.

Zhu D, Liu M, Yang Y, Ma L, Jiang Y, Zhou L, Huang Q, Pi R, Chen X. Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 2013;556:76–79.

Juhn J, Lee J, Byun JK, Kim EW, Lee JH, Kwok SK, Ju JH, Park KS, Kim HY, et al. Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17/Treg balance, and osteoclastogenesis in mice and human. Mediators Inflamm 2014;2014:31586.

Yang XP, Goreschi K, Steward-Tharp SM, Rodriguez-Canales JZ, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAG5. Nat Immunol 2011;12:247–54.

Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol 2000;20:126–47.

Nankivel BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:349–56.

Kim YR, Yang CS. Protective roles of ginseng against bacterial infection. Microb Pathog 2005;39:15–9.

Shea JJ. T cell-directed therapies: lessons learned and future prospects. Clin Immunol 2004;108:1–12.

Wang J, Li A, Duan H, Meng Z, Tan J, Yan H, Yu Z. Human P-glycoprotein involvement in cyclosporine nephrotoxicity: association with mutual regulation of RelA (p65)/NF-kappaB and phospho-IkappaB in the CNS. Biochem Biophys Res Commun 2011;414:464–70.

Oh CH, Soo EK. Efficacy of Korean red ginseng in the treatment of alopecia areata. J Ginseng Res 2012;36:391–5.

Zhu D, Liu M, Yang Y, Ma L, Jiang Y, Zhou L, Huang Q, Pi R, Chen X. Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 2013;556:76–79.

Juhn J, Lee J, Byun JK, Kim EW, Lee JH, Kwok SK, Ju JH, Park KS, Kim HY, et al. Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17/Treg balance, and osteoclastogenesis in mice and human. Mediators Inflamm 2014;2014:31586.